Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PYX-201 in Advanced Solid Tumors
NCT05720117Phase 1Recruiting
- Sponsor
- Pyxis Oncology
- Start
- Mar 2023
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of micvotabart pelidotin in solid tumor, breast cancer, triple-negative breast cancer (TNBC) and 1 more (5 arms), sponsored by Pyxis Oncology. Primary endpoints: Dose-limiting Toxicity at 21 days, Safety and Tolerability at 3 years and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
micvotabart pelidotin
03
Conditions
solid tumorbreast cancertriple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05720117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720117.